Cvrx, Inc. (CVRX) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Cvrx, Inc. is a commercial-stage medical device company focused on the Barostim system, a neuromodulation therapy for heart failure with reduced ejection fraction (HFrEF) and resistant hypertension. The company operates primarily in the U.S. and Europe, with revenue derived from direct sales to hospitals and distributors.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $14.8 million | $12.3 million |
| Gross Profit | $12.9 million | $10.3 million |
| Gross Margin | 87% | 84% |
| Net Loss | $(13.1) million | $(13.8) million |
| Net Loss Per Share | $(0.50) | $(0.53) |
| Cash and Equivalents | $72.3 million | $102.7 million (Q1 2025 end) |
| Long-Term Debt | $58.5 million | $49.5 million (Dec 31, 2025) |
| Operating Cash Flow | $(12.2) million | $(12.8) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 20% year-over-year, driven by a 22% increase in U.S. sales ($13.7M vs. $11.2M). U.S. revenue units rose to 429 from 359. European revenue remained flat at $1.1 million.
- Margin Expansion: Gross margin improved to 87% from 84%, attributed to higher average selling prices and manufacturing efficiencies reducing cost per unit.
- Expense Management: Operating expenses increased 5% to $25.0 million. R&D expenses rose 23% due to consulting and compensation costs, while SG&A increased 3% primarily due to compensation and stock-based compensation.
- Debt Financing: In January 2026, the company amended its Loan Agreement, increasing the total facility to $100 million and extending the maturity to 2031. The company drew an additional $10 million, bringing total outstanding term loans to $60 million.
- Commercial Expansion: Active implanting centers in the U.S. grew to 257 from 227, and sales territories expanded to 56 from 45.
Guidance, Outlook, and Risks
- Clinical Trials: The company initiated the BENEFIT-HF trial in Q1 2026, a prospective, multi-center randomized controlled trial evaluating all-cause mortality and HF decompensation. Enrollment is expected to begin in H1 2026 across ~150 centers.
- Reimbursement: Category I CPT codes for Barostim replaced Category III codes on January 1, 2026, eliminating automatic denials. While the 30-day approval rate for Medicare Advantage prior authorizations increased to 46% in Q1 2026, management noted temporary delays in approval speed due to regulatory changes.
- Liquidity: Management believes existing cash resources and operating cash flows will meet requirements for at least the next two years. A new At-The-Market (ATM) offering agreement with Jefferies LLC allows for up to $50 million in equity sales.
- Risks: Key risks include continued operating losses, dependence on the single Barostim product, reimbursement challenges, supply chain dependencies, and the potential for clinical trial results to be inconclusive.
Investor Verification Checklist
- Verify the sustainability of the 87% gross margin as production volumes scale.
- Monitor the 30-day prior authorization approval rates for Medicare Advantage payers following the CPT code transition.
- Track enrollment progress and interim data from the newly initiated BENEFIT-HF clinical trial.
- Assess the impact of the $60 million debt load on future interest expenses and covenant compliance (specifically the 50% trailing twelve-month revenue target).
- Review the utilization of the new $50 million ATM facility and potential dilution effects.